A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients
A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients
Simple item page
Full item details
- dc.contributor.author
- Naveed, Zaeema
- Li, Julia
- Naus, Monika
- Velásquez García, Héctor Alexander
- Wilton, James
- Janjua, Naveed Z.
- Canadian Immunization Research Network Provincial Collaborative Network investigators
- dc.date.accessioned
- 2025-02-10T16:31:37Z
- dc.date.available
- 2025-02-10T16:31:37Z
- dc.date.issued
- 2023-06
- dc.description.abstract - en
- <p>Objectives<br> We aimed to estimate the rate of myocarditis after the messenger RNA (mRNA) COVID-19 booster vaccination by vaccine type, age, and sex.</p> <p>Methods<br> We used data from the British Columbia COVID-19 Cohort, a population-based cohort surveillance platform. The exposure was a booster dose of an mRNA vaccine. The outcome was diagnosis of myocarditis during hospitalization or an emergency department visit within 7-21 days of booster vaccination.</p> <p>Results<br> The overall rate of myocarditis was lower for the booster dose (6.41, 95% confidence interval [CI]: 3.50-10.75) than the second dose (17.97, 95% CI: 13.78-23.04); (Rate ratiobooster vs dose-2 = 0.34, 95% CI: 0.17-0.61). This difference was more apparent for the mRNA-1273 vaccine type. After the second dose, the myocarditis rate in males was significantly lower for BNT162b2 than mRNA-1273 overall and among those aged 18-39 years. In contrast, after the booster dose, no significant differences between myocarditis and vaccine type was observed overall or within the specific age groups among males or females.</p> <p>Conclusion<br> Myocarditis after mRNA COVID-19 vaccines is a rare event. A lower absolute risk of myocarditis was observed after a booster dose of mRNA vaccine than the primary series second dose.</p>
- dc.description.sponsorship
- This work was supported by the Canadian Immunization Research Network through a grant from the Public Health Agency of Canada and the Canadian Institutes of Health Research (CNF 151944). This project was also supported by funding from the Public Health Agency of Canada through the Vaccine Surveillance Reference Group and the COVID-19 Immunity Task Force.
- dc.identifier.doi
- https://doi.org/10.1016/j.ijid.2023.03.027
- dc.identifier.issn
- 1878-3511
- dc.identifier.pubmedID
- 36967038
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3416
- dc.language.iso
- en
- dc.publisher - en
- International Society for Infectious Diseases
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- Epidemiology
- Coronavirus diseases
- Immunization
- dc.subject - fr
- Santé
- Épidémiologie
- Maladie à coronavirus
- Immunisation
- dc.subject.en - en
- Health
- Epidemiology
- Coronavirus diseases
- Immunization
- dc.subject.fr - fr
- Santé
- Épidémiologie
- Maladie à coronavirus
- Immunisation
- dc.title - en
- A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients
- dc.type - en
- Article
- dc.type - fr
- Article
- local.article.journaltitle - en
- International Journal of Infectious Diseases
- local.article.journalvolume
- 131
- local.pagination
- 75-78
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: naveed-myocarditis-messenger-rna-covid-19-booster-vaccination-adult-recipients.pdf
Size: 320.81 KB
Format: PDF
Collection(s)